| Realtime | Geld | Brief | Zeit |
|---|---|---|---|
| 0,338 | 0,342 | 02.03. | |
| 0,335 | 0,353 | 02.03. |
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 24.02. | Cosmos Health appoints AI drug discovery expert to advisory board | 4 | Investing.com | ||
| 24.02. | Cosmos Health Inc.: Cosmos Health Appoints Globally Recognized AI-Driven Drug Discovery and Clinical-Stage Biotech Expert Dr. Dimitrios Iliopoulos to Advisory Board | 535 | GlobeNewswire (Europe) | CHICAGO, Feb. 24, 2026 (GLOBE NEWSWIRE) -- Cosmos Health Inc. ("Cosmos Health" or the "Company") (NASDAQ:COSM), a diversified, vertically integrated global healthcare group, today announced the appointment... ► Artikel lesen | |
| COSMOS HEALTH Aktie jetzt für 0€ handeln | |||||
| 19.02. | Cosmos Health Inc.: Cosmos Health Highlights Approximately $15 Million Fair Market Value of Real Estate Assets, Exceeding Current Market Capitalization; Evaluates Monetization Options to Address Significant Discount to Book Value | 459 | GlobeNewswire (Europe) | CHICAGO, Feb. 19, 2026 (GLOBE NEWSWIRE) -- Cosmos Health Inc. ("Cosmos Health" or the "Company") (NASDAQ:COSM), a diversified, vertically integrated global healthcare group, today highlighted the intrinsic... ► Artikel lesen | |
| 18.02. | Cosmos Health: Hautreiniger C-Scrub bei britischer Kette Superdrug gelistet | 1 | Investing.com Deutsch | ||
| 18.02. | Cosmos Health's antimicrobial skin cleanser now available at Superdrug | 1 | Investing.com | ||
| 18.02. | Cosmos Health Inc.: Cosmos Health Continues UK Retail Expansion for C-Scrub; Now Available at Superdrug, the UK's Second-Largest Beauty and Health Retailer | 578 | GlobeNewswire (Europe) | CHICAGO, Feb. 18, 2026 (GLOBE NEWSWIRE) -- Cosmos Health Inc. ("Cosmos Health" or the "Company") (NASDAQ:COSM), a diversified, vertically integrated global healthcare group, today announced continued... ► Artikel lesen | |
| 18.02. | Cosmos Health's antimicrobial cleanser now available at Tesco | 3 | Investing.com | ||
| 18.02. | Cosmos Health Inc.: Cosmos Health Announces Growing Momentum for C-Scrub in the United Kingdom; Now Available at Tesco, the UK's Largest Retailer | 531 | GlobeNewswire (Europe) | CHICAGO, Feb. 18, 2026 (GLOBE NEWSWIRE) -- Cosmos Health Inc. ("Cosmos Health" or the "Company") (NASDAQ:COSM), a diversified, vertically integrated global healthcare group, today announced a significant... ► Artikel lesen | |
| 17.02. | Cosmos Health Inc.: Cosmos Health Showcases Expanding Brand Portfolio at World Health Expo Dubai 2026 | 804 | GlobeNewswire (Europe) | CHICAGO, Feb. 17, 2026 (GLOBE NEWSWIRE) -- Cosmos Health Inc. ("Cosmos Health" or the "Company") (NASDAQ:COSM), a diversified, vertically integrated global healthcare group, today announced its participation... ► Artikel lesen | |
| 11.02. | Cosmos Health Inc.: Cosmos Health Expands Digital Assets Program with $500,000 Bitcoin Purchase, Bringing Total Cryptocurrency Investments to $2.5 Million; Evaluates Inclusion of Other Select Cryptocurrencies | 803 | GlobeNewswire (Europe) | CHICAGO, Feb. 11, 2026 (GLOBE NEWSWIRE) -- Cosmos Health Inc. ("Cosmos Health" or the "Company") (NASDAQ:COSM), a diversified, vertically integrated global healthcare group, today announced the expansion... ► Artikel lesen | |
| 20.01. | Cosmos Health Inc.: Cosmos Health Announces Accelerating Customer Growth, Improving Unit Economics and Robotic Expansion Supporting $40M in Additional Annual Revenue | 1.254 | GlobeNewswire (Europe) | CHICAGO, Jan. 20, 2026, a diversified, vertically integrated global healthcare group, today announced continued operational growth and infrastructure expansion at Cosmofarm, its pharmaceutical distribution... ► Artikel lesen | |
| 20.01. | Cosmos Health reports 20% customer growth at Greek subsidiary | 5 | Investing.com | ||
| 14.01. | Cosmos Health Inc.: Cosmos Health Announces Initiation of Analyst Coverage with $4.50 Valuation by Zacks Small-Cap Research | 12 | GlobeNewswire (USA) | ||
| 05.01. | Cosmos Health: Aktie legt nach Produktionsvereinbarung mit Libytec zu | 7 | Investing.com Deutsch | ||
| 05.01. | Cosmos Health Inc.: Cosmos Health Enters Manufacturing Agreement with Libytec for PathMuscle Medicine, with Five-Year Volumes Expected to Exceed 1.2 Million Units | 383 | GlobeNewswire (Europe) | CHICAGO, Jan. 05, 2026, a diversified, vertically integrated global healthcare group, today announced that its wholly owned subsidiary, Cana Laboratories, has entered into a manufacturing and supply... ► Artikel lesen | |
| 05.01. | Cosmos Health to manufacture PathMuscle drug for Greek distributor | 2 | Investing.com | ||
| 24.12.25 | Cosmos Health Is Building a Platform, and Tariffs Are Accelerating the Strategy | 487 | ACCESS Newswire | CHICAGO, IL / ACCESS Newswire / December 24, 2025 / Healthcare investors have seen this movie before. A company leans hard on a single product, rides momentum while it lasts, then scrambles when conditions... ► Artikel lesen | |
| 19.12.25 | Hawk Point Media: Cosmos Health is Forcing the Market to Reframe the Conversation | 358 | ACCESS Newswire | CHICAGO, IL / ACCESS Newswire / December 19, 2025 / For a long stretch, Cosmos Health (NASDAQ:COSM) sat in a familiar category. A company investors respected, followed, and occasionally revisited, but... ► Artikel lesen | |
| 18.12.25 | Cosmos Health Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 03.12.25 | Cosmos Health partners with Prime Ledger for digital transformation | 2 | Investing.com |
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| NOVO NORDISK | 32,155 | -0,05 % | ANALYSE-FLASH: JPMorgan senkt Novo Nordisk auf 'Neutral' und Ziel auf 250 Kronen | NEW YORK (dpa-AFX) - Die US-Bank JPMorgan hat das Kursziel für Novo Nordisk nach der enttäuschenden Cagrisema-Vergleichsstudie von 350 auf 250 dänische Kronen gesenkt und die Aktien von "Overweight"... ► Artikel lesen | |
| PFIZER | 23,350 | +0,19 % | Amt warnt vor Honigpaste mit verstecktem Viagra-Wirkstoff | TÜBINGEN (dpa-AFX) - Das Landratsamt Tübingen warnt vor dem Verzehr einer bei Amazon verkauften Honigpaste - weil ein verstecktes Potenzmittel drin ist. Das Nahrungsergänzungsmittel "Lotus Mixed Herbal... ► Artikel lesen | |
| NOVARTIS | 143,24 | +0,14 % | Novartis tritt in Indien den Rückzug an, um sich in Zukunft noch mehr auf das US-Geschäft konzentrieren zu können | Seit rund einem Jahr verstärkt Novartis seine Bemühungen um den US-Markt. Aus Furcht vor der trumpschen Zollkeule kündigte das Schweizer Unternehmen im vergangenen Frühjahr an, 23 Milliarden US-Dollar... ► Artikel lesen | |
| AURORA CANNABIS | 3,170 | -0,63 % | Is Aurora Cannabis Stock Ready to 10X in the Next Pot Boom? | ||
| SANOFI | 81,64 | +0,15 % | Regeneron und Sanofi erhalten Empfehlung für erweiterte Dupixent-Zulassung | DJ Regeneron und Sanofi erhalten Empfehlung für erweiterte Dupixent-Zulassung
Von Colin Kellaher
DOW JONES--Der Ausschuss für Humanarzneimittel (CHMP) der Europäischen Arzneimittel-Agentur... ► Artikel lesen | |
| GSK | 24,930 | -0,44 % | JPMORGAN stuft GSK auf 'Underweight' | NEW YORK (dpa-AFX Analyser) - Die US-Bank JPMorgan hat die Einstufung für GSK nach einer Telefonkonferenz auf "Underweight" mit einem Kursziel von 1700 Pence belassen. Mit einer Übernahme von 35Pharma... ► Artikel lesen | |
| CANOPY GROWTH | 0,937 | +0,86 % | Is It Time to Dump Your Shares of Canopy Growth?? | ||
| STADA ARZNEIMITTEL | - | - | Pharmakonzern Stada: Nachträglich mehr Geld für Aktionäre | Hartnäckigkeit kann sich für Anleger auszahlen. Zur Höhe der gezahlten Abfindung beim Stada-Squeeze-Out sind immer noch Klagen ehemaliger Aktionäre anhängig. So ist der aktuelle Stand. Der Hintergrund:... ► Artikel lesen | |
| ELI LILLY | 872,30 | +0,21 % | Novo Nordisk setzt Eli Lilly unter Druck | Im frühen US-Handel zählen die Anteilscheine von Eli Lilly zu den schwächsten Titeln. Denn der dänische Rivale Novo Nordisk plant deutliche Preissenkungen für seine Blockbuster-Medikamente in den USA.... ► Artikel lesen | |
| MERCK & CO | 104,00 | +0,19 % | Leerink raises Merck stock price target on belzutifan growth | ||
| TILRAY BRANDS | 6,560 | +0,77 % | MDMA-Herausforderer Bioxyne punktet mit 112% Umsatzplus. Und was macht Tilray? | ||
| TEVA | 28,900 | 0,00 % | Teva Pharmaceutical Industries Ltd: Teva to Present at the Upcoming Investor Conferences in March | PARSIPPANY, N.J. and TEL AVIV, Israel, Feb. 24, 2026 (GLOBE NEWSWIRE) -- Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) today announced that Richard Francis, Teva's President and CEO, will... ► Artikel lesen | |
| VERTEX PHARMACEUTICALS | 417,75 | +0,44 % | Vertex Pharmaceuticals Inc. Reports Rise In Q4 Bottom Line | CAMBRIDGE (MASSACHUSETTS) (dpa-AFX) - Vertex Pharmaceuticals Inc. (VRTX) reported earnings for its fourth quarter that Increases, from last yearThe company's earnings came in at $1.191 billion... ► Artikel lesen | |
| INNOCAN PHARMA | 4,280 | +2,88 % | Innocan Pharma Corporation: FDA Center for Veterinary Medicine Grants Innocan a Fee Waiver in 2026 for the Third Consecutive Time | HERZLIYA, Israel and CALGARY, AB, Feb. 27, 2026 /PRNewswire/ -- Innocan Pharma Corporation (CSE: INNO) (FSE: IP40) (OTCQB: INNPD) ("Innocan" or the "Company"),... ► Artikel lesen | |
| ABBOTT LABORATORIES | 98,23 | +0,65 % | Exact Sciences (EXAS) Merger with Abbott Moving Forward After Shareholder Approval |